Autoantibodies in rheumatoid arthritis: a review

Mewar, Devesh; Wilson, Anthony G.

doi:10.1016/j.biopha.2006.09.002

Cited by 77 publications

(70 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…B cell regulation is disturbed in RA, as evidenced by elevated levels of various autoantibodies, such as rheumatoid factor, autoantibodies to cyclic citrullinated peptide, type II collagen (CII), glucose-6-phosphate isomerase, and many other self antigens (1). The observation that some of these are arthritogenic in animal models emphasizes the importance of antibodies and B cells in arthritis disease induction.…”

Section: Conclusion Ides Has Therapeutic Potential In Igg Antibody-mmentioning

confidence: 99%

Blocking of experimental arthritis by cleavage of IgG antibodies in vivo

Nandakumar¹,

Johansson²,

Björck³

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To investigate whether IgG-degrading enzyme of Streptococcus pyogenes (IdeS), a bacterial cysteine endopeptidase that cleaves human IgG in the hinge region, can be used for blocking the development of arthritis.Methods. Recombinant IdeS was purified and tested for specificity against mouse IgG. IdeS was injected intravenously into mice with collagen antibodyinduced arthritis (CAIA), collagen-induced arthritis (CIA), or relapsing CIA, and its effects on arthritis development and severity were assessed. Results. IdeS efficiently cleaved mouse

show abstract

Section: Conclusion Ides Has Therapeutic Potential In Igg Antibody-mmentioning

confidence: 99%

Blocking of experimental arthritis by cleavage of IgG antibodies in vivo

Nandakumar¹,

Johansson²,

Björck³

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…In recent years, a variety of additional autoantibodies have been described in patients with RA (reviewed in ref. [19]). Antibodies against citrulline containing proteins anticitrullinated protein/peptide antibodies (ACPA) have shown to be highly specific for RA (specificity: 96-98% [20,21]), without compromising their sensitivity.…”

Section: Serological Markers and Autoantigen Discoverymentioning

confidence: 99%

Proteomics in rheumatology: The beginning of a fairy tale?

Lambrecht

Tilleman

Elewaut

et al. 2008

Proteomics Clinical Apps

View full text Add to dashboard Cite

One of the major challenges in proteome research is to translate its applications to the setting of human diseases. Proteomics in rheumatology is an area with marked potential including applications ranging from diagnostics, over therapeutic monitoring to discovery of new potential therapeutic targets. Biomarkers will be essential to discriminate between clinical similar rheumatic diseases, to monitor disease-states or to install the best appropriate therapy. Especially in the field of rheumatology, analysis of specific genes and/or their expression products by pharmacogenetics/-genomics or pharmacoproteomics could be necessary to enable an effective, patient-tailored therapy. In rheumatology, direct examination of proteins may be of utmost importance, as it is already known that PTMs, such as citrullination of proteins or peptides, may be involved in certain rheumatic diseases. The discovery and validation of antibodies directed against citrullinated proteins/peptides in rheumatic diseases using proteome analysis approaches has been described. Gel-free methods, SELDI-approaches and classic 2-DE approaches have been deployed on body fluids as well as on target tissues in different rheumatic diseases. Proteomics in rheumatology is on the rise and pilot studies have indicated that the application of proteomicsbased technologies in rheumatic diseases appears to be an exciting example of translational research.

show abstract

“…RF is specific to the Fc portion of other immunoglobulin molecules whereas anti-CCP antibodies bind citrullinated peptides. Both antibodies have been found to precede the onset of RA symptoms and are associated with a more severe disease outcome [3]. Neither factor is 100% sensitive or specific to the diagnosis of RA.…”

Section: Autoantibody Productionmentioning

confidence: 99%

Role of B Cells in Rheumatic Autoimmune Disease

Hogan¹,

Wheater²,

Huigens³

et al. 2010

Open Arth J

View full text Add to dashboard Cite

Abstract:There is increasing evidence that B cells can play important roles in the pathogenesis of various autoimmune diseases, either by autoantibody secretion, production of proinflammatory cytokines or autoantigen presentation. An increasing number of B cell directed therapies are in development as a possible treatment strategy of rheumatic autoimmune diseases, such as Rituximab which targets the B cell specific CD20 surface marker. This article provides an overview of the principal understandings of B cell immunology in autoimmunity and selected rheumatic autoimmune diseases.

show abstract

Autoantibodies in rheumatoid arthritis: a review

Cited by 77 publications

References 115 publications

Blocking of experimental arthritis by cleavage of IgG antibodies in vivo

Blocking of experimental arthritis by cleavage of IgG antibodies in vivo

Proteomics in rheumatology: The beginning of a fairy tale?

Role of B Cells in Rheumatic Autoimmune Disease

Contact Info

Product

Resources

About